The only approved entirely human monoclonal antibody Ilaris continuously neutralizes interleukin-1 beta thereby inhibiting inflammation.
Novartis division head David Epstein said, "When approved, lIaris will provide a new treatment option for patients who have endured frequent and crippling gouty arthritis attacks and where existing therapies do not offer relief."
If approved, Ilaris will be indicated for adult patients with frequent gouty arthritis attacks and provide pain relief by means of a 150mg single subcutaneous injection.